To cite this paper use one of the standards below:
Cannabis sativa is a plant from the family Cannabaceae which presents in its leaves bioactive compounds with properties that act in diverse pathologies and, as a result, there was an increase of its constituents’ intake, mainly as teas and oils. Tea and cannabis oil contain substances, such as cannabidiol, which are known worldwide for having momentary effects on diseases related to the central nervous system (CNS). In some countries such as the United States, cannabidiol is being evaluated as a dietary supplement for the treatment and prevention of some metabolic syndromes. Cannabidiol is a compound which has anti-inflammatory and antioxidant properties and therefore can act in the treatment of diseases such as diabetes, in addition to the treatment of diseases related to the CNS. This syndrome is directly related to the CNS because the diabetic patient has a characteristic hyperglycemic state which increases the oxidative stress in tissues that are susceptible to secondary complications such as dementia. Both diabetes and dementia affect mainly the elderly people and the treatment with cannabidiol has been studied because of its protective effect on the CNS. However, the results are controversial and it is still necessary to conduct more studies about the properties of the drug in the peripheral system. Therefore, the aim of this study was to evaluate the peripheral effects of the treatment with cannabidiol in diabetic, ischemic and elderly animals. It was used 350-day-old male Wistar streptozotocin-induced diabetic rats. Ischemia was induced by the 4-VO/ ICA surgical model, where the carotid and vertebral arteries were occluded, reducing the flow of cerebral oxygen. Four diabetic groups were established: Sham Diabetic Treated (SDT), Ischemic Diabetic Treated (DIT), Sham Diabetic Vehicle (SDV) and Ischemic Diabetic Vehicle (DIV), the vehicle groups were not treated with cannabidiol. A non-diabetic control group (ND) was also established. The animals were treated (10 mg/kg of body weight per day) for a period of 30 days. The glycemia and body weight were weekly evaluated and, at the end of the treatment, blood samples were collected and organs were removed and weighed. Blood glucose concentrations, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, fructosamine, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were evaluated. The DIT group presented a reduction in hyperglycemia during treatment, but it did not change the body weight values, unlike the group which was also treated with cannabidiol, but was not ischemic (SDT). The DIT group presented even lower values of fructosamine, LDL, HDL, triglycerides and total cholesterol. The treated but not ischemic group (SDT) demonstrated a reduction in the parameters of AST, ALT and in the liver weight. Treatment with cannabidiol showed important results in diabetic and ischemic animals, especially in relation to the hyperglycemic, lipidic and hepatic parameters, which were superior in regard to the untreated animals, and such results may contribute to the treatment of several pathologies with this compound, besides increasing the applications of the leaves from Cannabis sativa in different foods.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper